solution peptides tirzepatide Research Peptide | cGMP Tirzepatide 10mg — GLP-1/GIP Dual-Agonist

The Phase 2 trial (Jastreboff et al., NEJM 2023) identified gastrointestinal effects as the most common adverse events

Blood sugar stabilizes, liver fat decreases, blood pressure and cholesterol drop, sleep quality improves, and joint pain often eases

Focus on high-quality protein sources like lean meats, poultry, fish, eggs, dairy, legumes, tofu, and quinoa

Securing supply for these blockbusters has been high on the agenda for both Eli Lilly and fellow GLP-1 developers, including Novo Nordisk, which reported 2023 sales from its own diabetes and weight loss semuglatide products Ozempic and Wegovy of $13.7 billion and $4.5 billion, respectively

If weight loss stops for more than three months despite lifestyle modifications, consult your GP